Abciximab

Abciximab is a mouse or human chimeric monoclonal antibody that blocks IIb/IIIa receptors. It prevents clotting or sticking of platelets (blood cell) together. Abciximab is a new drug and has been approved by the FDA as an adjunctive therapy in patients undergoing high risk angioplasty and atherectomy.

Brands
REOPRO CLOTINAB
Adult Dose
Dose: 0.25 ug/kg/min
Single Dose: 0.25 (0.25)
Frequency: 24 hourly
Route: IV Inf
Instructions: Maintenance, for 12 hours
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
. It is of Combo1 origin. It belongs to Adenosine uptake inhibitor pharmacological group on the basis of mechanism of action.
Contraindications
Abciximab is contraindicated in conditions like Thrombocytopenia,Cerebrovascular accident,Hypersensitivity,GI bleeding,Vasculitis,Bleeding diathesis,Intracranial neoplasm,Active internal bleeding,Severe uncontrolled hypertension.
Effects
The severe or irreversible adverse effects of Abciximab, which give rise to further complications include Thrombocytopenia, Sinus bradycardia.Abciximab produces potentially life-threatening effects which include Bleeding, Anaphylaxis, Stroke. which are responsible for the discontinuation of Abciximab therapy.The symptomatic adverse reactions produced by Abciximab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Fever, Confusion, Hypotension, Backache, Vasculitis, Hematoma, Vision disturbances.
Indications
Abciximab is primarily indicated in conditions like A variety of solid tumors, Acute leukemia, Adjunct to angioplasty, Chronic lymphocytic leukaemia, Lymphomas, Moderate to severe reflux oesophagitis, Myocardial infarction prophylaxis, Secondry bacterial infection of acute bronchitis, and can also be given in adjunctive therapy as an alternative drug of choice in 5-fu therapy, Abdominal bleeding.
Interactions
Abciximab is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementHeparin (Na) and Heparin (Cl)ReteplaseConcurrent use may increase the risk of bleeding.TenecteplaseConcurrent use is usually not recommended but may be required in some cases. If both medicines are prescribed together, change of dose may be required.Tirofiban HClTrastuzumab These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj Store in refrigerator. Do not Freeze.
Warnings
Abciximab should be used with caution in patients with pre-existing illnesses, allergy, recent surgery or trauma. It should not be used if there is any bleeding (e.g. gastrointestinal bleeding) or history of stroke. Abciximab should be used carefully in patients weighing less than 75 Kg or older than 65 years or have a history of gastrointestinal disease. Use with caution during pregnancy and lactation.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.